Last reviewed · How we verify
Botulinum Toxin Type A for Injection
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | Botulinum Toxin Type A for Injection |
|---|---|
| Also known as | HengLi®, Botulinum toxin type A for injection (Hengli National Drug approval number S10970037) |
| Sponsor | Lanzhou Institute of Biological Products Co., Ltd |
| Drug class | Neurotoxin; neuromuscular blocking agent |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa); acetylcholine release machinery |
| Modality | Small molecule |
| Therapeutic area | Neurology; Dermatology; Aesthetics |
| Phase | Phase 3 |
Mechanism of action
The toxin is a zinc-dependent endopeptidase that cleaves SNAP-25 (synaptosome-associated protein of 25 kDa), preventing acetylcholine vesicles from fusing with the presynaptic membrane. This results in flaccid paralysis of injected muscles that typically lasts 3–4 months. The effect is reversible as the body gradually regenerates new SNARE proteins and neuromuscular junctions recover.
Approved indications
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
- Spasticity
- Chronic migraine
- Hyperhidrosis
- Cosmetic use (facial wrinkles)
Common side effects
- Injection site pain or bruising
- Headache
- Muscle weakness or paralysis (off-target)
- Ptosis (eyelid drooping)
- Dry mouth
- Neck pain
Key clinical trials
- DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia (PHASE1, PHASE2)
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (PHASE3)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine (PHASE3)
- Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury (PHASE3)
- Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment (NA)
- A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: